

## CGT Exome v3.2.3

Patient Information		Sample Information		Clinic Information	
Unique pat id.:	0065936 - 1542839	Sample type:	Blood	Clinic:	WeFIV
Patient name:		Date of draw:	26/04/2022	Doctor:	FLORENCIA DATRI
Patient DOB:		Date of receipt:	28/04/2022		
Ethnic group:	No family history	Report date/time:	04/07/2024		12:48

Indication:

### TEST RESULTS

## POSITIVE

The individual is carrier of:

### Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Gene :	CYP21A2	Allele:	Het
DNA Change:	NM_000500.9:c.844G>T	Inheritance:	AR
Protein change:	p.Val282Leu	OMIM phenotype:	201910
Variant classification:	Pathogenic		

### Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency

Gene :	RAPSN	Allele:	Het
DNA Change:	NM_005055.4:c.264C>A	Inheritance:	AR
Protein change:	p.Asn88Lys	OMIM phenotype:	208150; 616326
Variant classification:	Pathogenic		

### Parkinson disease, type 2, juvenile

Gene :	PRKN	Allele:	Het
DNA Change:	NM_004562.2:c.1310C>T	Inheritance:	AR
Protein change:	p.Pro437Leu	OMIM phenotype:	600116
Variant classification:	Pathogenic		

### Phenylketonuria

Gene :	PAH	Allele:	Het
DNA Change:	NM_000277.1:c.631C>A	Inheritance:	AR
Protein change:	p.Pro211Thr	OMIM phenotype:	261600
Variant classification:	Pathogenic		

### Tay-Sachs disease

Gene :	HEXA	Allele:	Het
DNA Change:	NM_001318825.1:c.772C>T	Inheritance:	AR
Protein change:	p.Arg258Trp	OMIM phenotype:	272800
Variant classification:	Pathogenic		

Patient name / DOB: MALENA CORONEL - 26/09/2001  
Report date/time: 04/07/2024 12:48

## Thrombocytopenia-absent radius syndrome

<b>Gene :</b>	RBM8A	<b>Allele:</b>	Het
<b>DNA Change:</b>	NM_005105.4:c.-21G>A	<b>Inheritance:</b>	AR
<b>Protein change:</b>	-	<b>OMIM phenotype:</b>	274000
<b>Variant classification:</b>	Pathogenic		

### INTERPRETATION OF TEST RESULTS

Typically, a positive result does not have direct clinical consequences for the carrier individual. There is another normal gene copy for all positive autosomal recessive (AR) genes indicated in the table which provides normal biological information. The likelihood of transmission of the variant(s) to offspring is 50%, independent for each variant. If the partner, or gamete donor, screens negative for the pathogenic or likely pathogenic variants in the gene(s) included in the table for this patient, the reproductive risk would be reduced. Please note that family members may also carry the variant(s) reported here, and this information may be significant for them and their offspring.

If a patient and partner, or gamete donor, are both carriers of variants in the same gene associated with AR inheritance, there is a 25% chance that any child they have together would be affected. If a female patient is a carrier for an X-linked condition, there is a 50% chance that each of the reproductive couple's children would also be a carrier. Males would typically express symptoms of the condition, and females are typically unaffected or may display milder symptoms.

For genes with a negative test result, the risk of having children affected by the associated disorders decreases significantly compared to the general population. This also the case for a negative personal result when a reproductive partner or a gamete donor is a carrier for a pathogenic or likely pathogenic variant in one or more of the tested genes. However, due to test limitations associated with any genetic test, this low risk is not zero (see limitations section and informed consent form).

### LOW COVERAGE VARIANTS

HSD11B2:NM\_000196.3:c.77\_78delCA;NAGLU:NM\_000263.3:c.245G>A;NEK1:NM\_001199397.1:c.3616G>T;SURF1:NM\_003172.3:c.32\_38dupTGCGGGC;GCSH:NM\_004483.4:c.1A>G;NDUF6:NM\_152416.3:c.2T>C;PANK2:NM\_153638.3:c.445G>T. These variants have a coverage lower than 7X and it is not possible to determine if they are present or not in the sample (non-informative variants).

### TEST DESCRIPTION

The Carrier Genetic Test (CGT) is a preconception DNA screening test that aims to identify individuals and couples at increased risk of conceiving children affected by a monogenic disease. Knowledge of this risk may influence a couple's decision to conceive or encourage the couple to adopt preventive measures, including preimplantation genetic testing for the at risk disease (PGT-M) prenatal genetic testing, or to use donated gametes. The multigene CGT interrogates thousands of DNA variants using a high-throughput technology (Next Generation Sequencing, NGS).

### COMMENTS

Language changed.

### TEST METHODOLOGY

1. DNA extraction from the biological sample. 2. Next Generation Sequencing of gene regions where known mutations are located (list available at <https://cgt.igenomix.com/diseases-list/>). 3. Raw data analysis using bioinformatics (bioinformatic pipeline v1.0). QC parameters require that more than 99.7% of the tested variants have coverage greater than the minimum read depth (7x). 4. Complementary testing by other techniques for: a) SMN1 gene: exon 7 deletion; b) CYP21A2 gene: frequent mutations; c) HBA1/HBA2 genes: frequent deletions; d) FMR1 gene: CGG repeat sizing (females only); e) DMD gene: frequent deletions/duplications; f) F8 gene: intron 22 inversion (females only); g) FXN gene: GAA repeat sizing.

Patient name / DOB: MALENA CORONEL - 26/09/2001

Report date/time: 04/07/2024 12:48

## TEST LIMITATIONS

The CGT test only includes analysis of the specific variants included into the list (list of variants analyzed are available by request), and no others. Therefore, the CGT test does not cover all monogenic diseases nor 100% of disease-causing mutations for each tested gene. The test does not include the analysis of conditions associated with mitochondrial DNA, multifactorial, digenic or dominant inheritance. The test does not detect large rearrangements (inversions, deletions and duplications more than 15 nucleotides), mutations located in regulatory regions or intronic regions outside the +/-3bp cut off or in low sequence coverage areas. DNA changes caused by trinucleotide repeat expansions are not detected, except those indicated in the methodology section. For copy number variation analysis, when a normal result is obtained (2 copies detected), it is not possible to be certain that the two copies are each in one of the two alleles (non-carrier) or if both are in the same allele (cis) and no copies in the other (silent carrier). Finally, if our assessment of a variant fails to meet our QC parameters due to low coverage, a result for the variant(s) will not be issued.

The analytical detection rate is higher than 99%. The clinical sensitivity varies among conditions (e.g.: for HEXB gene, 30% of affected patients are carriers of a 16 kb deletion that is not included in the test). The sensitivity for SMN1 is approximately 96% because point mutations or small ins/del are not analyzed and, for a normal result (2 copies detected), it is not possible to be certain that the two copies are each in one of the two alleles (non-carrier) or if both are in the same allele (cis) and no copies in the other (carrier).

A negative result for the variants included in CGT does not exclude the possibility of being a carrier. The presence of pseudogenes and/or rare polymorphisms and/or homopolymers may lead to false negative or false positive results. A negative result for the CGT variants does not exclude the possibility of a de novo mutation being present in the offspring. In the general population there is a 3-5% risk for birth defects caused by genetic and/or non-genetic factors not detected by this type of test. Germline mosaicism or low-level somatic mosaicism cannot be detected. As with any laboratory test, there is a small chance that this result may be inaccurate for a procedural reason such as an error during sample collection, labelling, processing, data collection or interpretation. Please note that the classification of variants can change over time. To check whether there have been any changes to the classification of reported variants, please contact IGENOMIX.

## LEGAL/QUALITY

This test was developed, and its performance characteristics determined by Igenomix Group. It has not been cleared or approved by the US Food and Drug Administration. The test is used as a laboratory developed test for clinical purposes. \*IGENOMIX SPAIN holds CLIA Certificate of Compliance: #99D2146167. Part of this test has been outsourced to a referral laboratory whose QMS is based on high Quality Standards, periodically monitored by Igenomix SPAIN and audited by independent external parties.

## EXEMPTION CLAUSE OF DIAGNOSTIC LIABILITY

The genetic diagnosis services carried out by IGENOMIX ARGENTINA S.A are exclusively intended to be interpreted by qualified/certified health professionals.

**The result obtained by this test and the information that could be derived from it, cannot be considered in any case as substitute of genetic counselling or medical treatment by a trained professional neither represent itself a medical enquiry. We recommend that you consult your physician for genetic testing & counselling upon reception of your results.**

Any result should be interpreted in the context of all available clinical findings, within the general context of a medical investigation, which must be conducted by clinically trained professionals. IGENOMIX ARGENTINA S.A is not responsible for any decisions made or actions undertaken by the contracting party based on the results provided by IGENOMIX ARGENTINA S.A or otherwise., nor the harmful temporary consequences diverted by its use, making specific discretion of taking appropriate legal measures assuming an improper use of those mentioned studies and analysis.

Patient name / DOB: MALENA CORONEL - 26/09/2001

Report date/time: 04/07/2024 12:48

**SIGNED**



**Camila Ayala Lira da Cruz**  
CRBIO 113163  
Bióloga

**COUNTERSIGNED**



**Lic. Daniela Lorenzi**  
Manager de Laboratorio

This test or part of this test has been outsourced to a referral Laboratory (IGENOMIX Group) Lab CLIA No.: 99D2146167



Patient name / DOB: MALENA CORONEL - 26/09/2001  
Report date/time: 04/07/2024 12:48

## Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

### What is Congenital adrenal hyperplasia due to 21-hydroxylase deficiency?

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the CYP21A2 gene located on chromosomal region 6p21.3. The age of onset is neonatal/infantile. This disease is characterized by simple virilizing or salt wasting forms that can manifest with genital ambiguity in females, and in both sexes with adrenal insufficiency with dehydration during the neonatal period, life threatening hypoglycemia and hyperandrogenia. The prevalence is 1/100,000 to 9/100,000. There is a common milder form of congenital adrenal hyperplasia (Nonclassic) characterized by a later onset of androgen excess symptoms seen in females and precocious pseudopuberty in both sexes. Cortisol and aldosterone levels are normal but there is an increased amount of androgens. Nonclassic form onset occurs in adolescence with variable degrees of postnatal androgen excess (precocious pubarche, hirsutism, acne, alopecia, anovulation and menstrual irregularities and in the post-pubertal period it can mimic polycystic ovary syndrome. It is also sometimes asymptomatic. The prevalence ranges from 1/1,000-1/500 in the general Caucasian population, but up to 1-2% among inbred populations, such as Eastern European (Ashkenazi) Jews.

### What is the next step if I am a carrier of Congenital adrenal hyperplasia due to 21-hydroxylase deficiency?

If you are a carrier of Congenital adrenal hyperplasia due to 21-hydroxylase deficiency it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

### What if my partner isn't a carrier?


If your partner tests negative for Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

### What if both parents are carriers of Congenital adrenal hyperplasia due to 21-hydroxylase deficiency?

When both parents are carriers of Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

### What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Patient name / DOB: MALENA CORONEL - 26/09/2001

Report date/time: 04/07/2024 12:48

## Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency

### What is Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency?

Fetal akinesia deformation sequence follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the RAPSN gene located on chromosomal region 11p11.2. The age of onset is early. This disease is characterized by multiple joint contractures, facial anomalies and pulmonary hypoplasia. The prevalence is 1:3,000. Mutation in the RAPSN gene can also cause a form of congenital myasthenic syndrome (CMS11) associated with acetylcholine receptor (AChR) deficiency. CMS11 associated with AChR deficiency is a disorder of the postsynaptic neuromuscular junction (NMJ) clinically characterized by early-onset muscle weakness with variable severity.

### What is the next step if I am a carrier of Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency?

If you are a carrier of Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

#### What if my partner isn't a carrier?


If your partner tests negative for Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

### What if both parents are carriers of Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency?

When both parents are carriers of Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

#### What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



## Parkinson disease, type 2, juvenile

### What is Parkinson disease, type 2, juvenile?

Parkinson disease, type 2, juvenile (PARK2) is a neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, tremor, and onset usually before 40. It differs from classic Parkinson disease by early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. Dementia is absent. Pathologically, patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent.

### What is the next step if I am a carrier of Parkinson disease, type 2, juvenile?

If you are a carrier of Parkinson disease, type 2, juvenile it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

### What if my partner isn't a carrier?


If your partner tests negative for Parkinson disease, type 2, juvenile, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

### What if both parents are carriers of Parkinson disease, type 2, juvenile?

When both parents are carriers of Parkinson disease, type 2, juvenile, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

### What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Patient name / DOB: MALENA CORONEL - 26/09/2001  
Report date/time: 04/07/2024 12:48

## Phenylketonuria

### What is Phenylketonuria?

Phenylketonuria follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the PAH gene located on chromosomal region 12q23.2. The age of onset is neonatal. This disease is characterized by gradual developmental delay, stunted growth, microcephaly, seizures, tremors, eczema, vomiting, and musty odor. Untreated patients subsequently develop intellectual disability, behavioral disorders (hyperactivity) and motor disorders. The prevalence is 1:2,600-1:200,000.

### What is the next step if I am a carrier of Phenylketonuria?

If you are a carrier of Phenylketonuria it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

### What if my partner isn't a carrier?


If your partner tests negative for Phenylketonuria, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

### What if both parents are carriers of Phenylketonuria?

When both parents are carriers of Phenylketonuria, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

### What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Patient name / DOB: MALENA CORONEL - 26/09/2001  
Report date/time: 04/07/2024 12:48

## Tay-Sachs disease

### What is Tay-Sachs disease?

Tay-Sachs disease follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the HEXA gene located on chromosomal region 15q23. The age of onset is infantile. There are three forms, type 1 (infantile), with a psychomotor retardation which is associated with hypotonia, amaurosis and megalencephaly. Type 2 is characterized by locomotor ataxia, behavioural disorders, and progressive loss of intellectual capacities. Type three (chronic form) shows spinocerebellar ataxia or spinal amyotrophy. The prevalence is 1 case per 320 000 live births.

### What is the next step if I am a carrier of Tay-Sachs disease?

If you are a carrier of Tay-Sachs disease it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

### What if my partner isn't a carrier?


If your partner tests negative for Tay-Sachs disease, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

### What if both parents are carriers of Tay-Sachs disease?

When both parents are carriers of Tay-Sachs disease, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

### What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Patient name / DOB: MALENA CORONEL - 26/09/2001  
Report date/time: 04/07/2024 12:48

## Thrombocytopenia-absent radius syndrome

### What is Thrombocytopenia-absent radius syndrome?

The thrombocytopenia-absent radius syndrome (TAR) is characterized by reduction in the number of platelets and absence of the radius; preservation of the thumb distinguishes TAR from other syndromes that combine blood abnormalities with absence of the radius, such as Fanconi anemia (227650). Individuals with TAR have low numbers of megakaryocytes, platelet precursor cells that reside in bone marrow, and frequently present with bleeding episodes in the first year of life that diminish in frequency and severity with age. The severity of skeletal anomalies varies from absence of radii to virtual absence of upper limbs, with or without lower limb defects such as malformations of the hip and knee (Albers et al., 2012).

### What is the next step if I am a carrier of Thrombocytopenia-absent radius syndrome?

If you are a carrier of Thrombocytopenia-absent radius syndrome it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

### What if my partner isn't a carrier?


If your partner tests negative for Thrombocytopenia-absent radius syndrome, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

### What if both parents are carriers of Thrombocytopenia-absent radius syndrome?


When both parents are carriers of Thrombocytopenia-absent radius syndrome, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

### What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Patient name / DOB: MALENA CORONEL - 26/09/2001

Report date/time: 04/07/2024 12:48



LIST OF ANALYZED GENES

AAAS, AARS1, AARS2, AASS, ABAT, ABCA1, ABCA12, ABCA3, ABCA4, ABCB11, ABCB4, ABCC2, ABCC6, ABCC8, ABCD1, ABCD4, ABCG5, ABCG8, ABDH12, ABDH5, ACAD8, ACAD9, ACADM, ACADS, ACADSB, ACADVL, ACAT1, ACE, ACO2, ACOX1, ACOX2, ACP5, ACSF3, ACTA1, ACY1, ADA, ADA2, ADAM9, ADAMTS10, ADAMTS13, ADAMTS17, ADAMTS18, ADAMTS2, ADAMTS2L, ADAMTS4, ADAR, ADAT3, ADGRG1, ADGRG6, ADGRV1, ADK, ADSL, ADSS1, AFF2, AFG3L2, AFP, AGA, AGLB5, AGK, AGL, AGPAT2, AGPS, AGRN, AGT, AGTR1, AGXT, AHY, AHI1, AICDA, AIMP1, AIMP2, AIPL1, AIRE, AK1, AK2, AKR1C2, AKR1D1, ALAD, ALB, ALDH18A1, ALDH3A2, ALDH4A1, ALDH5A1, ALDH7A1, ALDOA, ALDOB, ALG1, ALG11, ALG12, ALG2, ALG3, ALG6, ALG8, ALG9, ALMS1, ALOX12B, ALOXE3, ALPK3, ALPL, ALS2, ALX1, ALX3, ALX4, APCR, AMB, AMBN, AMH, AMHR2, AMN, AMPD1, AMPD2, AMT, ANGPTL3, ANKSG, ANO10, ANO5, ANTXR1, ANTXR2, AP1S1, AP1S2, AP3B1, AP3B2, AP3D1, AP4B1, AP4E1, AP4M1, AP4S1, AP5Z1, APOC2, APOE, APMT, AQP2, AR, ARFGF2, ARG1, ARHGAD1A, ARHGFE18, ARL13B, ARL2BP, ARL6, ARMCO9, ARPC1B, ARSA, ARSB, ARSL, ARV1, ARX, ASAH1, ASL, ASNS, ASPA, ASPH, ASPM, ASS1, ATAD1, ATO6, ATIC, ATM, ATOH7, ATP13A2, ATP2A1, ATP6V0A2, ATP6V0A4, ATP6V1A, ATP6V1B1, ATP6V1E1, ATP7A, ATP7B, ATP8B1, ATR, ATRX, AUH, AURKC, AVIL, B2M, B3GALNT2, B3GALT6, B3GAT3, B3GLCT, B4GALNT1, B4GALT1, B4GALT7, B4GAT1, B9D1, B9D2, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, BCAT2, BCHE, BCKDHA, BCKDHB, BCKDK, BCL10, BCS1L, BEST1, BFP51, BHLHA9, BIN1, BLM, BLNK, BLOC1S3, BLOC1S6, BLVRA, BMP1, BMPER, BMPR1B, BOLA3, BPGM, BPNT2, BRAT1, BRF1, BRP1, BRWD3, BSCL2, BSND, BTD, BTK, BUB1B, C12orf57, C12orf65, C19orf12, C1QA, C1QB, C1QBP, C1QC, C1S, C2, C2CD3, C3, C5, C6, C7, C8B, C8orf37, CA12, CA2, CASA, CA8, CABP2, CABP4, CACNA1D, CACNA2D4, CAD, CALCR1, CANT1, CAPN1, CAPN3, CARD11, CARD9, CAR5, CASQ2, CASR, CAST, CAT, CATSPER1, CAVIN1, CBLIF, CBS, CC2D1A, CC2D2A, CCEB1, CCDC103, CCDC115, CCDC174, CCDC39, CCDC40, CCDC65, CCDC8, CCDC88C, CN6, CCNO, CD19, CD247, CD27, CD2AP, CD320, CD36, CD3D, CD3E, CD3G, CD40, CD40LG, CD55, CD59, CD79A, CD79B, CD81, CD8A, CDAN1, CD1C4A, CD45, CDCA7, CDH11, CDH23, CDH3, CDHR1, CDIN1, CDK10, CDK5RAP2, CDSN, CRT1, CEBPE, CENPF, CENPJ, CEP104, CEP120, CEP135, CEP152, CEP164, CEP19, CEP290, CEP41, CEP55, CEP57, CEP78, CEP83, CERKL, CERSS3, CFP43, CFP45, CFP5, CFH, CFH1, CFL2, CFTR, CHAT, CHKB, CHM, CHMP1A, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHST14, CHST3, CHST6, CHST7, CHST8, CHST9, C11orf97, C11orf98, C11orf99, C11orf100, C11orf101, C11orf102, C11orf103, C11orf104, C11orf105, C11orf106, C11orf107, C11orf108, C11orf109, C11orf110, C11orf111, C11orf112, C11orf113, C11orf114, C11orf115, C11orf116, C11orf117, C11orf118, C11orf119, C11orf120, C11orf121, C11orf122, C11orf123, C11orf124, C11orf125, C11orf126, C11orf127, C11orf128, C11orf129, C11orf130, C11orf131, C11orf132, C11orf133, C11orf134, C11orf135, C11orf136, C11orf137, C11orf138, C11orf139, C11orf140, C11orf141, C11orf142, C11orf143, C11orf144, C11orf145, C11orf146, C11orf147, C11orf148, C11orf149, C11orf150, C11orf151, C11orf152, C11orf153, C11orf154, C11orf155, C11orf156, C11orf157, C11orf158, C11orf159, C11orf160, C11orf161, C11orf162, C11orf163, C11orf164, C11orf165, C11orf166, C11orf167, C11orf168, C11orf169, C11orf170, C11orf171, C11orf172, C11orf173, C11orf174, C11orf175, C11orf176, C11orf177, C11orf178, C11orf179, C11orf180, C11orf181, C11orf182, C11orf183, C11orf184, C11orf185, C11orf186, C11orf187, C11orf188, C11orf189, C11orf190, C11orf191, C11orf192, C11orf193, C11orf194, C11orf195, C11orf196, C11orf197, C11orf198, C11orf199, C11orf200, C11orf201, C11orf202, C11orf203, C11orf204, C11orf205, C11orf206, C11orf207, C11orf208, C11orf209, C11orf210, C11orf211, C11orf212, C11orf213, C11orf214, C11orf215, C11orf216, C11orf217, C11orf218, C11orf219, C11orf220, C11orf221, C11orf222, C11orf223, C11orf224, C11orf225, C11orf226, C11orf227, C11orf228, C11orf229, C11orf230, C11orf231, C11orf232, C11orf233, C11orf234, C11orf235, C11orf236, C11orf237, C11orf238, C11orf239, C11orf240, C11orf241, C11orf242, C11orf243, C11orf244, C11orf245, C11orf246, C11orf247, C11orf248, C11orf249, C11orf250, C11orf251, C11orf252, C11orf253, C11orf254, C11orf255, C11orf256, C11orf257, C11orf258, C11orf259, C11orf260, C11orf261, C11orf262, C11orf263, C11orf264, C11orf265, C11orf266, C11orf267, C11orf268, C11orf269, C11orf270, C11orf271, C11orf272, C11orf273, C11orf274, C11orf275, C11orf276, C11orf277, C11orf278, C11orf279, C11orf280, C11orf281, C11orf282, C11orf283, C11orf284, C11orf285, C11orf286, C11orf287, C11orf288, C11orf289, C11orf290, C11orf291, C11orf292, C11orf293, C11orf294, C11orf295, C11orf296, C11orf297, C11orf298, C11orf299, C11orf300, C11orf301, C11orf302, C11orf303, C11orf304, C11orf305, C11orf306, C11orf307, C11orf308, C11orf309, C11orf310, C11orf311, C11orf312, C11orf313, C11orf314, C11orf315, C11orf316, C11orf317, C11orf318, C11orf319, C11orf320, C11orf321, C11orf322, C11orf323, C11orf324, C11orf325, C11orf326, C11orf327, C11orf328, C11orf329, C11orf330, C11orf331, C11orf332, C11orf333, C11orf334, C11orf335, C11orf336, C11orf337, C11orf338, C11orf339, C11orf340, C11orf341, C11orf342, C11orf343, C11orf344, C11orf345, C11orf346, C11orf347, C11orf348, C11orf349, C11orf350, C11orf351, C11orf352, C11orf353, C11orf354, C11orf355, C11orf356, C11orf357, C11orf358, C11orf359, C11orf360, C11orf361, C11orf362, C11orf363, C11orf364, C11orf365, C11orf366, C11orf367, C11orf368, C11orf369, C11orf370, C11orf371, C11orf372, C11orf373, C11orf374, C11orf375, C11orf376, C11orf377, C11orf378, C11orf379, C11orf380, C11orf381, C11orf382, C11orf383, C11orf384, C11orf385, C11orf386, C11orf387, C11orf388, C11orf389, C11orf390, C11orf391, C11orf392, C11orf393, C11orf394, C11orf395, C11orf396, C11orf397, C11orf398, C11orf399, C11orf400, C11orf401, C11orf402, C11orf403, C11orf404, C11orf405, C11orf406, C11orf407, C11orf408, C11orf409, C11orf410, C11orf411, C11orf412, C11orf413, C11orf414, C11orf415, C11orf416, C11orf417, C11orf418, C11orf419, C11orf420, C11orf421, C11orf422, C11orf423, C11orf424, C11orf425, C11orf426, C11orf427, C11orf428, C11orf429, C11orf430, C11orf431, C11orf432, C11orf433, C11orf434, C11orf435, C11orf436, C11orf437, C11orf438, C11orf439, C11orf440, C11orf441, C11orf442, C11orf443, C11orf444, C11orf445, C11orf446, C11orf447, C11orf448, C11orf449, C11orf450, C11orf451, C11orf452, C11orf453, C11orf454, C11orf455, C11orf456, C11orf457, C11orf458, C11orf459, C11orf460, C11orf461, C11orf462, C11orf463, C11orf464, C11orf465, C11orf466, C11orf467, C11orf468, C11orf469, C11orf470, C11orf471, C11orf472, C11orf473, C11orf474, C11orf475, C11orf476, C11orf477, C11orf478, C11orf479, C11orf480, C11orf481, C11orf482, C11orf483, C11orf484, C11orf485, C11orf486, C11orf487, C11orf488, C11orf489, C11orf490, C11orf491, C11orf492, C11orf493, C11orf494, C11orf495, C11orf496, C11orf497, C11orf498, C11orf499, C11orf500, C11orf501, C11orf502, C11orf503, C11orf504, C11orf505, C11orf506, C11orf507, C11orf508, C11orf509, C11orf510, C11orf511, C11orf512, C11orf513, C11orf514, C11orf515, C11orf516, C11orf517, C11orf518, C11orf519, C11orf520, C11orf521, C11orf522, C11orf523, C11orf524, C11orf525, C11orf526, C11orf527, C11orf528, C11orf529, C11orf530, C11orf531, C11orf532, C11orf533, C11orf534, C11orf535, C11orf536, C11orf537, C11orf538, C11orf539, C11orf540, C11orf541, C11orf542, C11orf543, C11orf544, C11orf545, C11orf546, C11orf547, C11orf548, C11orf549, C11orf550, C11orf551, C11orf552, C11orf553, C11orf554, C11orf555, C11orf556, C11orf557, C11orf558, C11orf559, C11orf560, C11orf561, C11orf562, C11orf563, C11orf564, C11orf565, C11orf566, C11orf567, C11orf568, C11orf569, C11orf570, C11orf571, C11orf572, C11orf573, C11orf574, C11orf575, C11orf576, C11orf577, C11orf578, C11orf579, C11orf580, C11orf581, C11orf582, C11orf583, C11orf584, C11orf585, C11orf586, C11orf587, C11orf588, C11orf589, C11orf590, C11orf591, C11orf592, C11orf593, C11orf594, C11orf595, C11orf596, C11orf597, C11orf598, C11orf599, C11orf600, C11orf601, C11orf602, C11orf603, C11orf604, C11orf605, C11orf606, C11orf607, C11orf608, C11orf609, C11orf610, C11orf611, C11orf612, C11orf613, C11orf614, C11orf615, C11orf616, C11orf617, C11orf618, C11orf619, C11orf620, C11orf621, C11orf622, C11orf623, C11orf624, C11orf625, C11orf626, C11orf627, C11orf628, C11orf629, C11orf630, C11orf631, C11orf632, C11orf633, C11orf634, C11orf635, C11orf636, C11orf637, C11orf638, C11orf639, C11orf640, C11orf641, C11orf642, C11orf643, C11orf644, C11orf645, C11orf646, C11orf647, C11orf648, C11orf649, C11orf650, C11orf651, C11orf652, C11orf653, C11orf654, C11orf655, C11orf656, C11orf657, C11orf658, C11orf659, C11orf660, C11orf661, C11orf662, C11orf663, C11orf664, C11orf665, C11orf666, C11orf667, C11orf668, C11orf669, C11orf670, C11orf671, C11orf672, C11orf673, C11orf674, C11orf675, C11orf676, C11orf677, C11orf678, C11orf679, C11orf680, C11orf681, C11orf682, C11orf683, C11orf684, C11orf685, C11orf686, C11orf687, C11orf688, C11orf689, C11orf690, C11orf691, C11orf692, C11orf693, C11orf694, C11orf695, C11orf696, C11orf697, C11orf698, C11orf699, C11orf700, C11orf701, C11orf702, C11orf703, C11orf704, C11orf705, C11orf706, C11orf707, C11orf708, C11orf709, C11orf710, C11orf711, C11orf712, C11orf713, C11orf714, C11orf715, C11orf716, C11orf717, C11orf718, C11orf719, C11orf720, C11orf721, C11orf722, C11orf723, C11orf724, C11orf725, C11orf726, C11orf727, C11orf728, C11orf729, C11orf730, C11orf731, C11orf732, C11orf733, C11orf734, C11orf735, C11orf736, C11orf737, C11orf738, C11orf739, C11orf740, C11orf741, C11orf742, C11orf743, C11orf744, C11orf745, C11orf746, C11orf747, C11orf748, C11orf749, C11orf750, C11orf751, C11orf752, C11orf753, C11orf754, C11orf755, C11orf756, C11orf757, C11orf758, C11orf759, C11orf760, C11orf761, C11orf762, C11orf763, C11orf764, C11orf765, C11orf766, C11orf767, C11orf768, C11orf769, C11orf770, C11orf771, C11orf772, C11orf773, C11orf774, C11orf775, C11orf776, C11orf777, C11orf778, C11orf779, C11orf780, C11orf781, C11orf782, C11orf783, C11orf784, C11orf785, C11orf786, C11orf787, C11orf788, C11orf789, C11orf790, C11orf791, C11orf792, C11orf793, C11orf794, C11orf795, C11orf796, C11orf797, C11orf798, C11orf799, C11orf800, C11orf801, C11orf802, C11orf803, C11orf804, C11orf805, C11orf806, C11orf807, C11orf808, C11orf809, C11orf810, C11orf811, C11orf812, C11orf813, C11orf814, C11orf815, C11orf816, C11orf817, C11orf818, C11orf819, C11orf820, C11orf821, C11orf822, C11orf823, C11orf824, C11orf825, C11orf826, C11orf827, C11orf828, C11orf829, C11orf830, C11orf831, C11orf832, C11orf833, C11orf834, C11orf835, C11orf836, C11orf837, C11orf838, C11orf839, C11orf840, C11orf841, C11orf842, C11orf843, C11orf844, C11orf845, C11orf846, C11orf847, C11orf848, C11orf849, C11orf850, C11orf851, C11orf852, C11orf853, C11orf854, C11orf855, C11orf856, C11orf857, C11orf858, C11orf859, C11orf860, C11orf861, C11orf862, C11orf863, C11orf864, C11orf865, C11orf866, C11orf867, C11orf868, C11orf869, C11orf870, C11orf871, C11orf872, C11orf873, C11orf874, C11orf875, C11orf876, C11orf877, C11orf878, C11orf879, C11orf880, C11orf881, C11orf882, C11orf883, C11orf884, C11orf885, C11orf886, C11orf887, C11orf888, C11orf889, C11orf890, C11orf891, C11orf892, C11orf893, C11orf894, C11orf895, C11orf896, C11orf897, C11orf898, C11orf899, C11orf900, C11orf901, C11orf902, C11orf903, C11orf904, C11orf905, C11orf906, C11orf907, C11orf908, C11orf909, C11orf910, C11orf911, C11orf912, C11orf913, C11orf914, C11orf915, C11orf916, C11orf917, C11orf918, C11orf919, C11orf920, C11orf921, C11orf922, C11orf923, C11orf924, C11orf925, C11orf926, C11orf927, C11orf928, C11orf929, C11orf930, C11orf931, C11orf932, C11orf933, C11orf934, C11orf935, C11orf936, C11orf937, C11orf938, C11orf939, C11orf940, C11orf941, C11orf942, C11orf943, C11orf944, C11orf945, C11orf946, C11orf947, C11orf948, C11orf949, C11orf950, C11orf951, C11orf952, C11orf953, C11orf954, C11orf955, C11orf956, C11orf957, C11orf958, C11orf959, C11orf960, C11orf961, C11orf962, C11orf963, C11orf964, C11orf965, C11orf966, C11orf967, C11orf968, C11orf969, C11orf970, C11orf971, C11orf972, C11orf973, C11orf974, C11orf975, C11orf976, C11orf977, C11orf978, C11orf979, C11orf980, C11orf981, C11orf982, C11orf983, C11orf984, C11orf985, C11orf986, C11orf987, C11orf988, C11orf989, C11orf990, C11orf991, C11orf992, C11orf993, C11orf994, C11orf995, C11orf996, C11orf997, C11orf998, C11orf999, C11orf1000, C11orf1001, C11orf1002, C11orf1003, C11orf1004, C11orf1005, C11orf1006, C11orf1007, C11orf1008, C11orf1009, C11orf1010, C11orf1011, C11orf1012, C11orf1013, C11orf1014, C11orf1015, C11orf1016, C11orf1017, C11orf1018, C11orf1019, C11orf1020, C11orf1021, C11orf1022, C11orf1023, C11orf1024, C11orf1025, C11orf1026, C11orf1027, C11orf1028, C11orf1029, C11orf1030, C11orf1031, C11orf1032, C11orf1033, C11orf1034, C11orf1035, C11orf1036, C11orf1037, C11orf1038, C11orf1039, C11orf1040, C11orf1041, C11orf1042, C11orf1043, C11orf1044, C11orf1045, C11orf1046, C11orf1047, C11orf1048, C11orf1049, C11orf1050, C11orf1051, C11orf1052, C11orf1053, C11orf1054, C11orf1055, C11orf1056, C11orf1057, C11orf1058, C11orf1059, C11orf1060, C11orf1061, C11orf1062, C11orf1063, C11orf1064, C11orf1065, C11orf1066, C11orf1067, C11orf1068, C11orf1069, C11orf1070, C11orf1071, C11orf1072, C11orf1073, C11orf1074, C11orf1075, C11orf1076, C11orf1077, C11orf1078, C11orf1079, C11orf1080, C11orf1081, C11orf1082, C11orf1083, C11orf1084, C11orf1085, C11orf1086, C11orf1087, C11orf1088, C11orf1089, C11orf1090, C11orf1091, C11orf1092, C11orf1093, C11orf1094, C11orf1095, C11orf1096, C11orf1097, C11orf1098, C11orf1099, C11orf1100, C11orf1101, C11orf1102, C11orf1103, C11orf1104, C11orf1105, C11orf1106, C11orf1107, C11orf1108, C11orf1109, C11orf1110, C11orf1111, C11orf1112, C11orf1113, C11orf1114, C11orf1115, C11orf1116, C11orf1117, C11orf1118, C11orf1119, C11orf1120, C11orf1121, C11orf1122, C11orf1123, C11orf1124, C11orf1125, C11orf1126, C11orf1127, C11orf1128, C11orf1129, C11orf1130, C11orf1131, C11orf1132, C11orf1133, C11orf1134, C11orf1135, C11orf1136, C11orf1137, C11orf1138, C11orf1139, C11orf1140, C11orf1141, C11orf1142, C11orf1143, C11orf1144, C11orf1145, C11orf1146, C11orf1147, C11orf1148, C11orf1149, C11orf1150, C11orf1151, C11orf1152, C11orf1153, C11orf1154, C11orf1155, C11orf1156, C11orf1157, C11orf1158, C11orf1159, C11orf1160, C11orf1161, C11orf1162, C11orf1163, C11orf1164, C11orf1165, C11orf1166, C11orf1167, C11orf1168, C11orf1169, C11orf1170, C11orf1171, C11orf1172, C11orf1173, C11orf1174, C11orf1175, C11orf1176, C11orf1177, C11orf1178, C11orf1179, C11orf1180, C11orf1181, C11orf1182, C11orf1183, C11orf1184, C11orf1185, C11orf1186, C11orf1187, C11orf1188, C11orf1189, C11orf1190, C11orf1191, C11orf1192, C11orf1193, C11orf1194, C11orf1195, C11orf1196, C11orf1197, C11orf1198, C11orf1199, C11orf1200, C11orf1201, C11orf1202, C11orf1203, C11orf1204, C11orf1205, C11orf1206, C11orf1207, C11orf1208, C11orf1209, C11orf1210, C11orf1211, C11orf1212, C11orf1213, C11orf1214, C11orf1215, C11orf1216, C11orf1217, C11orf1218, C11orf1219, C11orf1220, C11orf1221, C11orf1222, C11orf1223, C11orf1224, C11orf1225, C11orf1226, C11orf1227, C11orf1228, C11orf1229, C11orf1230, C11orf1231, C11orf1232, C11orf1233, C11orf1234, C11orf1235, C11orf1236, C11orf1237, C11orf1238, C11orf1239, C11orf1240, C11orf1241, C11orf1242, C11orf1243, C11orf1244, C11orf1245, C11orf1246, C11orf1247, C11orf1248, C11orf1249, C11orf1250, C11orf1251, C11orf1252, C11orf1253, C11orf1254, C11orf1255, C11orf1256, C11orf1257, C11orf1258, C11orf1259, C11orf1260, C11orf1261, C11orf1262, C11orf1263, C11orf1264, C11orf1265, C11orf1266, C11orf1267, C11orf1268, C11orf1269, C11orf1270, C11orf1271, C11orf1272, C11orf1273, C11orf1274, C11orf1275, C11orf1276, C11orf1277, C11orf1278, C11orf1279, C11orf1280, C11orf1281, C11orf1282, C11orf1283, C11orf1284, C11orf1285, C11orf1286, C11orf1287, C11orf1288, C11orf1289, C11orf1290, C11orf1291, C11orf1292, C11orf1293, C11orf1294, C11orf1295, C11orf1296, C11orf1297, C11orf1298, C11orf1299, C11orf1300, C11orf1301, C11orf1302, C11orf1303, C11orf1304, C11orf1305, C11orf1306, C11orf1307, C11orf1308, C11orf1309, C11orf1310, C11orf1311, C11orf1312, C11orf1313, C11orf1314, C11orf1315, C11orf1316, C11orf1317, C11orf1318, C11orf1319, C11orf1320, C11orf1321, C11orf1322, C11orf1323, C11orf1324, C11orf1325, C11orf1326, C11orf1327, C11orf1328, C11orf1329, C11orf1330, C11orf1331, C11orf1332, C11orf1333, C11orf1334, C11orf1335, C11orf1336, C11orf1337, C11orf1338, C11orf1339, C11orf1340, C11orf1341, C11orf1342, C11orf1343, C11orf1344, C11orf1345, C11orf1346, C11orf1347, C11orf1348, C11orf1349, C11orf1350, C11orf1351, C11orf1352, C11orf1353, C11orf1354, C11orf1355, C11orf1356, C11orf1357, C11orf1358, C11orf1359, C11orf1360, C11orf1361, C11orf1362, C11orf1363, C11orf1364, C11orf1365, C11orf1366, C11orf1367, C11orf1368, C11orf1369, C11orf1370, C11orf1371, C11orf1372, C11orf1373, C11orf1374, C11orf1375, C11orf1376, C11orf1377, C11orf1378, C11

Patient name / DOB: MALENA CORONEL - 26/09/2001  
Report date/time: 04/07/2024 12:48

## GLOSSARY

### TYPES OF INHERITANCE:

- **AR: Autosomal recessive**  
Inherited conditions that require two pathogenic variants (one from each parent) in a given gene to display symptoms.
- **XR: X-linked recessive**  
The gene is located on the X chromosome. Men with a pathogenic variant have the disease. Women with a pathogenic variant are carriers and generally asymptomatic or may mild symptoms.
- **Digenic inheritance**  
In some diseases, the symptoms could be explained by the coexistence of pathogenic variants in two different genes related with the disease instead of two pathogenic variants in the same gene.

### ALLELES:

#### Pathogenic variants present in the two copies of a gene.

- **Homozygous pathogenic variant (Hom.):**  
Each copy of the gene has the same pathogenic variant. Generally, this is associated with clinical symptoms.
- **Compound heterozygous (Het.):**  
Each copy of the gene has a different pathogenic variant. Generally, this is associated with clinical symptoms. This situation is referred as having variants "in trans".

#### Pathogenic variant present in one copy of a gene.

- **Heterozygous pathogenic variant (Het.):**  
Only one copy of a gene has a pathogenic variant. There is another normal gene copy.

Note: Sometimes an individual has two pathogenic variants in the same gene copy. This situation is referred as having variants in cis and it is considered as a single pathogenic variant.

### CNV:

Refers to copy number variation (deletion or duplication), i.e., the number of copies of a particular gene (or gene region) is different from the usual two copies.

### LARGE GENE CONVERSION:

Refers to pathogenic variants caused by gene sequence exchange or replacement between a normal functional gene and a quasi-identical non-functional gene (pseudogene).